Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
5.26
+0.11+2.14%
TA
Loading chart...
Snapshot
| Index | - | P/E | 3.87 | EPS (ttm) | 1.36 | Insider Own | - | Shs Outstand | 80.03M | Perf Week | 1.54% |
| Market Cap | 420.94M | Forward P/E | - | EPS next Y | -1.48 | Insider Trans | 0.01% | Shs Float | 60.05M | Perf Month | -0.38% |
| Enterprise Value | 1.74M | PEG | - | EPS next Q | -0.51 | Inst Own | - | Short Float | 12.76% | Perf Quarter | 21.48% |
| Income | 122.00M | P/S | 1.20 | EPS this Y | -245.96% | Inst Trans | - | Short Ratio | 23.82 | Perf Half Y | -11.00% |
| Sales | 351.00M | P/B | 1.02 | EPS next Y | 25.44% | ROA | -71.16% | Short Interest | 7.66M | Perf YTD | 47.34% |
| Book/sh | 5.14 | P/C | 0.99 | EPS next 5Y | - | ROE | -64.25% | 52W High | 6.45 -18.45% | Perf Year | 77.10% |
| Cash/sh | 5.31 | P/FCF | - | EPS past 3/5Y | - | ROIC | -86.35% | 52W Low | 2.78 89.21% | Perf 3Y | 59.88% |
| Dividend Est. | - | EV/EBITDA | 0.01 | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 3.55% 3.97% | Perf 5Y | -81.65% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 168.00% | Oper. Margin | 0.00% | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.13 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 48.68 | Recom | 3.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.13 | EPS Q/Q | 6.82% | SMA20 | -3.17% | Beta | 0.39 | Target Price | 7.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 2.95% | Rel Volume | 0.85 | Prev Close | 5.15 |
| Employees | 55 | LT Debt/Eq | 0.00 | Earnings | Nov 11 | SMA200 | 11.91% | Avg Volume | 329.54K | Price | 5.26 |
| IPO Date | Oct 30, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 26.13% - | Net Debt/EBITDA | 0.44 | Volume | 279,428 | Change | 2.14% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Reiterated | Morgan Stanley | Equal Weight | $6.88 → $7.00 |
| Mar-09-26 | Reiterated | Evercore ISI Group | Outperform | $10 |
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal Weight | $6.88 |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight | |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal Weight → Underweight | |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Market Perform | |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral | |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal Weight |
Latest News· Times ET
Sep-15-26
Sep-15-2612:41PM
Sep-08-26
Sep-08-2603:00AM
Sep-02-26
Sep-02-2612:24AM
Aug-19-26
Aug-13-26
Aug-13-2606:15AM
Aug-12-26
02:05PM
Atea Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
12:05PM
Aug-05-26
Aug-05-2603:00AM
Jul-28-26
Jul-28-2606:13AM
03:00AM
Jul-14-26
Jul-14-2603:00AM
Jul-10-26
Jun-25-26
Company
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 351 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 168 | 0 | 83 | — | — | — | — | — | — | |
| Gross Profit | 184 | 0 | -83 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 46 | 33 | 49 | — | — | — | — | — | — | |
| Research and Development | 168 | 148 | 145 | — | — | — | — | — | — | |
| Other Operating Expense | -168 | 0 | -84 | — | — | — | — | — | — | |
| Operating Income | 139 | -181 | -193 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 16 | 25 | — | — | — | — | — | — | |
| Net Income Before Taxes | 139 | -165 | -167 | — | — | — | — | — | — | |
| Income Taxes | 17 | -6 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | 122 | -158 | -168 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 122 | -158 | -168 | — | — | — | — | — | — | |
| Net Income | 122 | -158 | -168 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.46 | -1.94 | -2.00 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.46 | -1.94 | -2.00 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.36 | -1.94 | -2.00 | — | — | — | — | — | — | |
| EBITDA | 139 | -164 | -132 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 3.87 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.24 | — | — | — | — | — | — | — | — | |
| Gross Margin | 52.42 | — | — | — | — | — | — | — | — | |
| Operating Margin | 39.60 | — | — | — | — | — | — | — | — | |
| Net Margin | 34.76 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 83 | 81 | 84 | — | — | — | — | — | — | |
| Market Capitalization | 437 | 289 | 281 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 536,097 | Jun 23 |
| DUNCAN BARBARA GAYLE | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 92,350 | Jun 23 |
| Polsky Bruce | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 124,806 | Jun 23 |
| Lucidi Bruno | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 142,350 | Jun 23 |
| Murphy Polly A. | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 121,745 | Jun 23 |
| Adams Jerome M. | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 92,350 | Jun 23 |
| Murphy Polly A. | Director | May 18 '26 | Buy | 4.17 | 6,100 | 25,446 | 92,145 | May 21 |
| Murphy Polly A. | Director | May 18 '25 | Buy | 4.17 | 6,100 | 25,446 | 92,145 | May 20 |
| Corcoran Andrea | See Remarks | Mar 11 '26 | Option Exercise | 1.24 | 120,000 | 148,800 | 823,576 | Mar 13 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | Feb 03 '26 | Option Exercise | 1.24 | 300,000 | 372,000 | 767,830 | Feb 03 |
| Horga Maria Arantxa | Chief Medical Officer | Jan 31 '26 | Option Exercise | 0.00 | 61,033 | 0 | 112,159 | Feb 03 |
| Vavricka John | Chief Commercial Officer | Jan 31 '26 | Option Exercise | 0.00 | 50,833 | 0 | 94,164 | Feb 03 |
| Hammond Janet MJ | Chief Development Officer | Jan 31 '26 | Option Exercise | 0.00 | 69,300 | 0 | 141,801 | Feb 03 |
| Corcoran Andrea | See Remarks | Jan 31 '26 | Option Exercise | 0.00 | 65,366 | 0 | 779,680 | Feb 03 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | Jan 31 '26 | Option Exercise | 0.00 | 372,500 | 0 | 573,923 | Feb 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.